Bristol-Myers Squibb Avapro
FDA requests additional information on studies supporting the promotional claim that the highest dose of Avapro (irbesartan, 300 mg once daily) reduces seated trough diastolic blood pressure more than the highest dose (100 mg daily) of Merck's Cozaar (losartan). FDA previously accepted two trials as evidence showing a superior effect for Avapro, however, the agency told Bristol April 6 that, "upon further review," FDA is asking for the protocol and complete set of data files from the "Oparil" study, a description of non-responders who were not titrated to a higher dose of either drug, the bioavailability of both products and an explanation of why there were fewer Avapro-treated patients included in the blood pressure analysis. Bristol submitted a prepublication manuscript for the Oparil trial in response to a March 25, 1998 FDA letter asserting that Bristol was making superiority claims on the basis of one unreplicated study ("The Pink Sheet" June 15, 1998, p. 19)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth